参芪扶正注射液联合多西紫杉醇加氟脲嘧啶/亚叶酸钙治疗晚期胃癌的临床观察

Clinical Observation on Treatment of Advanced Gastric Cancer by Combined Use of Shenqi Fuzheng Injection, Docetaxel, Flurouracil and Calcium Folinate

免费下载全文查看/发表评论下载PDF阅读器

DOI：

中文关键词: 胃癌参芪扶正注射液多西紫杉醇化疗生活质量

英文关键词:gastric cancer Shenqi Fuzheng Injection docetaxel chemotherapy quality of life

基金项目:

作者	单位
赵洁敏	江苏省常州市第一人民医院肿瘤科江苏213003
吴爱珍	江苏省常州市第一人民医院肿瘤科江苏213003
石亮荣	江苏省常州市第一人民医院肿瘤科江苏213003
杨轩璇	江苏省常州市第一人民医院肿瘤科江苏213003
李建华	江苏省常州市第一人民医院肿瘤科江苏213003
吴昌平	江苏省常州市第一人民医院肿瘤科江苏213003

摘要点击次数: 1232

全文下载次数: 2

中文摘要:

目的观察参芪扶正注射液联合多西紫杉醇加氟脲嘧啶/亚叶酸钙治疗晚期胃癌的临床效果及其减毒增效作用。方法60例晚期胃癌患者随机分为中药加化疗组和单纯化疗组各30例。化疗方案均采用多西紫杉醇75mg/m2静脉滴注1h,第1天;氟脲嘧啶(5-FU)350mg/m2用微量泵24h持续静脉滴注,第1～5天;亚叶酸钙(CF)120mg/m2静脉滴注,第1～5天。21～28天为1个周期。中药加化疗组于化疗前3天开始应用参芪扶正注射液250mL静脉滴注,每天1次,连用14天。2个周期后进行疗效评价。结果中药加化疗组和单纯化疗组近期有效率分别为40.0%和33.3%,差异无显著性(χ2=0.29,P>0.05)。中药加化疗组Karnorfsky评分(χ2=7.21,P<0.05)和体重(χ2=11.47,P<0.05)明显增加,外周血白细胞下降程度减轻,恢复快,胃肠道反应、末梢神经损伤较轻,化疗后免疫功能好于单纯化疗组。结论参芪扶正注射液能有效改善多西紫杉醇加氟脲嘧啶/亚叶酸钙联合化疗的临床症状,提高患者的生活质量,减轻化疗的不良反应,提高免疫功能。

英文摘要:

Objective To investigate the effects of Shenqi Fuzheng injection (SQFZI) combined with docetaxel, flurouracil and calcium folinate in treating advanced gastric carcinoma, and to evaluate the action of SQFZI for enhancing therapeutic effect and alleviating adverse reaction of chemotherapy. Methods Sixty advanced gastric cancer patients were assigned to two groups randomly, the control group treated with chemotherapy alone and the treated group treated with SQFZI combined chemotherapy. Chemotherapy regimens (TFC) was given to all patients consisting of docetaxel 75 mg/m2 intravenous dripping on the 1st day, flurouracil (5-FU) 350 mg/m2 and calcium folinate (CF) 120 mg/m2 intravenous dripping with micro-pump continuously from day 1 to 5, for 21-28 days as a cycle. To patients in the treated group, starting from 3 days before chemotherapy, SQFZI 250 mL was dripped every day for 14 successive days. The clinic effects were evaluated after two-cycle treatment. Results The short-term effective rate was 40.0% in the treated group and 33.3% in the control group. As compared with those in the control group, patients in the treated group after treatment had a higher Karnofsky score (χ2=7.21, P<0.05) and body weight (χ2=11.47,P<0.05), lesser adverse reactions in decreasing of peripheral blood leucocyte, damage of peripheral nerve, adverse reaction of gastrointestinal tract, as well as better immune function. Conclusion SQFZI could effectively improve the clinical symptoms induced by chemotherapy regimen TFC, alleviate the adverse reaction, raise patients’ quality of life and their immune function.

关闭